Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Completed · Phase 1/Phase 2

Conditions studied: Cystic Fibrosis

In brief

The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.

Key facts

Study ID

NCT00043316

Run by

InterMune

People needed

66

Starts

2001-02-01

Expected to finish

2002-10-01

Last updated by the study team

2007-11-01

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Palo Alto, California, United States
• Study site — Sacramento, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Denver, Colorado, United States
• Study site — Daytona Beach, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Rochester, Minnesota, United States
• Study site — New York, New York, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Nashville, Tennessee, United States
• Study site — Lackland Air Force Base, Texas, United States
• Study site — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.